查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020745

Gabapentin市場：策略洞察與預測（2026-2031年）

Gabapentin Market - Strategic Insights and Forecasts (2026-2031)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計Gabapentin市場將從 2026 年的 24 億美元成長到 2031 年的 30 億美元，複合年成長率為 4.6%。

全球Gabapentin市場由專利到期過期的仿製學名藥主導，自原廠藥 Neuronthin 的專利保護期結束後，其商業性格局發生了根本性的變化。Gabapentin最初是作為一種治療局部癲癇的抗驚厥藥物而開發的，如今已發展成為一種廣泛使用的鎮痛藥，主要用於治療神經性疼痛。低成本非專利藥的廣泛普及提高了藥物的可及性，使市場價值從高利潤的品牌藥銷售轉向大規模的非專利銷售量。該藥物已確立的療效、相對良好的副作用以及較寬的治療指數，鞏固了其作為慢性疼痛一線治療藥物的地位。目前，儘管面臨許多挑戰，包括監管審查的加強、因鴉片類藥物合併症風險而導致的處方限制以及所有細分市場價格的大幅下降，加巴噴丁市場仍在持續擴張。

市場促進因素

全球慢性神經病變疼痛疾病盛行率的上升是主要需求促進因素。帶狀皰疹後遺症神經痛、糖尿病神經病變及相關神經病變在老年人和代謝性疾病患者中更為常見，約四分之一的美國成年人報告患有慢性疼痛。如此龐大且持續成長的患者群體，對有效且易於獲得的藥物療法產生了持續且巨大的需求。另一個相關的結構性因素是全球鴉片類藥物處方量的下降。政府計畫和醫療保健系統為應對鴉片類藥物危機而採取的舉措，直接加速了非鴉片類鎮痛藥（儘管這些藥物並未被指定為鴉片類藥物）的臨床替代，使Gabapentin成為初級和專科醫療機構中一種經濟有效的首選替代方案。價格低廉的非專利藥的廣泛供應進一步降低了使用門檻，使其能夠滲透到各個醫療保健層級，包括巴西和中國等新興市場的大規模公共醫療保健系統。

市場限制因素

來自學名藥的激烈競爭是主要的結構性限制因素，導致價格持續下降，擠壓所有市場參與企業的利潤空間，並限制了對新品牌藥研發的投資。監管和臨床上對呼吸抑制風險的擔憂是另一個不利因素，尤其是在Gabapentin與鴉片類藥物或其他中樞神經系統抑制劑合併使用時。美國食品藥物管理局（FDA）已強制要求更新相關處方警告，對以往常見的聯合用藥模式施加了限制。在支付者和政策層面，英國國家醫療服務體系（NHS）和英國國家衛生與臨床最佳化研究所（NICE）的指南建議對慢性疼痛患者進行定期評估和試驗性停藥，並將長期處方限制在已證實的臨床需求範圍內。受管制藥物分類，例如美國的州級處方藥監測計畫（PDMP）和巴西國家衛生監督局（ANVISA）的C1類藥物清單，構成了處方壁壘，並抑制了主要區域市場的需求成長。原料藥製造地的供應鏈集中在印度和中國，這為成品的全球供應連續性帶來了地緣政治和物流的脆弱性。

對技術和細分市場的洞察

神經性疼痛適應症領域是需求最大且結構最穩固的類別，這主要得益於該藥物檢驗的作用機制：與電壓門控鈣離子通道的α-2-δ次單元結合，從而抑制異常神經訊號傳導。學名藥佔據了絕大部分市場佔有率，輝瑞的品牌藥如Neuronthin和Glarize僅佔據有限的市場佔有率，且僅限於FDA核准的特定適應症。主要的創新機會在於緩釋製劑，其具有更優的藥物動力學特性、更低的給藥頻率，並且在以商品化競爭為主導的市場中具有溢價潛力。醫院藥局是最大的分銷管道，這主要得益於處方中處方集的採納以及在外科和住院患者的多方面鎮痛方案中的高使用率。在這些情況下，Gabapentin可以減少鴉片類藥物的消耗並改善康復效果。在中國，省級採購競標和中國作為世界領先的原料藥生產國的地位，造就了獨特的市場動態，將大規模的國內需求與經濟高效的本地供應相結合。

競爭與策略展望

學名藥之間的競爭格局以銷售主導為主，營運效率、原料藥採購的成本領先優勢以及供應鏈韌性決定市場地位。梯瓦製藥憑藉大規模生產能力和與藥品福利管理機構（PBM）在多種劑型上的合約優勢，佔據了主導供應商的地位，擁有巨大的市場佔有率。魯賓製藥則利用其在印度垂直整合的原料藥和製劑生產體系，透過合規性和價格競爭力，在包括美國在內的高度監管市場中競爭。輝瑞製藥憑藉其自有品牌產品系列組合維持著傳統的市場地位，專注於與神經科建立聯繫並針對特定核准的適應症，但其Gabapentin的收入貢獻遠低於銷售量的學名藥公司。近期值得關注的進展包括：Sunshine BioPharma將於2025年6月在加拿大推出三種劑量的Gabapentin非專利藥膠囊；Lotus Pharmaceutical與Adalvo合作，將於2023年在韓國推出300/600毫克緩釋Gabapentin。這些進展反映了學名藥持續向服務不足的市場拓展國際市場。

結論

預計到2031年，Gabapentin市場將保持穩定、銷售驅動的成長，這主要得益於全球神經病變疼痛負擔的加重、鴉片類鎮痛藥使用結構性轉變以及不同醫療保健系統中非專利原料藥的持續供應。那些能夠將成本效益高的原料藥採購、嚴格的監管合規性以及對差異化主導製劑的重點投資相結合的公司，將更有利於在這個日益同質化的市場中保持競爭優勢。

本報告的主要益處

  • 深入分析：獲得跨地區、客戶群、政策、社會經濟因素、消費者偏好和產業領域的詳細市場洞察。
  • 競爭格局：我們了解主要企業的策略舉措，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策以開發新的收入來源。
  • 適合各類讀者：非常適合Start-Ups、研究機構、顧問公司、中小企業和大型企業。

我們的報告的使用範例

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

報告範圍

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 評估競爭對手的市場定位、策略和市場佔有率。
  • 細分市場和區域銷售成長及預測評估
  • 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章：引言

  • 市場概覽
  • 市場的定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年及預測年調查期

第2章：調查方法

  • 調查數據
  • 先決條件

第3章執行摘要

  • 調查要點

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章：Gabapentin市場：按類型分類

  • 非專利的
  • 品牌商品

第6章：Gabapentin市場：依應用領域分類

  • 癲癇
  • 神經性疼痛
  • 不寧腿
  • 其他

第7章：Gabapentin市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 其他

第8章：Gabapentin市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章：競爭環境與分析

  • 主要企業及策略分析
  • 市佔率分析
  • 合併、收購、協議和合作關係
  • 供應商競賽矩陣

第10章：公司簡介

  • Pfizer
  • Fierce Pharma
  • Mayo Clinic
  • Ralington Pharma
  • Teva Pharmaceuticals
  • Gralise
  • Glenmark Pharmaceuticals
  • Stensa Lifesciences
  • Rosemont Pharmaceuticals
  • Lupin
簡介目錄
Product Code: KSI061616216

The Gabapentin Market is projected to grow from USD 2.4 billion in 2026 to USD 3.0 billion in 2031, reflecting a 4.6% CAGR.

The global gabapentin market operates in a post-patent, generic-dominant paradigm that has fundamentally redefined its commercial dynamics since the expiration of the original Neurontin brand exclusivity. Originally developed as an anticonvulsant for partial seizures, gabapentin has evolved into a high-volume analgesic agent, primarily indicated for neuropathic pain conditions. The widespread availability of low-cost generic formulations has democratized access, shifting market value from high-margin branded revenues to large-scale generic volume throughput. The drug's established efficacy, relatively favorable side effect profile, and wide therapeutic index have cemented its role as a first-line treatment option in chronic pain management. Sustained expansion is now navigated against a backdrop of intensifying regulatory scrutiny, prescribing constraints linked to opioid co-administration risks, and the ongoing challenge of severe price compression across all market segments.

Market Drivers

The escalating global prevalence of chronic neuropathic pain conditions is the foremost demand driver. Postherpetic neuralgia, diabetic peripheral neuropathy, and related nerve damage disorders are highly prevalent in aging and metabolically compromised populations, with nearly a quarter of adults in the United States reporting chronic pain. This large, continuously growing patient pool creates persistent, high-volume demand for effective and accessible pharmacological management. A parallel structural driver is the global de-escalation of opioid prescribing. Government programs and health system initiatives targeting the opioid crisis have directly accelerated clinical substitution toward non-scheduled, non-opioid analgesics, elevating gabapentin as a preferred cost-effective alternative in primary and specialty care settings. The broad availability of generic formulations at accessible price points further lowers the barrier to adoption, enabling penetration across all healthcare tiers, including high-volume public health systems in emerging markets such as Brazil and China.

Market Restraints

Pervasive generic competition constitutes the primary structural constraint, driving sustained price erosion that compresses profit margins for all market participants and limits investment in novel branded development. Regulatory and clinical caution surrounding respiratory depression risk is a secondary headwind, particularly where gabapentin is co-prescribed with opioids or other Central Nervous System (CNS) depressants. The U.S. FDA has mandated updated prescribing warnings to this effect, imposing constraints on a previously common co-prescription pattern. At the payer and policy level, NHS and NICE guidelines in the United Kingdom recommend regular patient review and trial discontinuation for chronic pain indications, dampening long-term prescription volumes to verified clinical need. State-level Prescription Drug Monitoring Programs (PDMPs) in the United States, and controlled substance classifications such as ANVISA's List C1 designation in Brazil, add prescribing friction that moderates demand growth in key regional markets. Supply chain concentration in API manufacturing hubs in India and China introduces geopolitical and logistical vulnerability to the global supply continuity of finished dosage forms.

Technology and Segment Insights

The Neuropathic Pain application segment is the largest and most structurally entrenched demand category, driven by the drug's validated mechanism of binding to the alpha-2-delta subunit of voltage-gated calcium channels to suppress aberrant nerve signaling. The Generic type segment commands the overwhelming majority of market volume, with branded products such as Pfizer's Neurontin and Gralise retaining a narrow foothold limited to specific FDA-approved indications. The principal innovation opportunity lies in extended-release (ER) formulations, which offer improved pharmacokinetic profiles, reduced dosing frequency, and potential for premium pricing in a market otherwise defined by commodity competition. Hospital Pharmacy represents the largest distribution channel, driven by formulary inclusion and high utilization in multimodal analgesia protocols for surgical and inpatient settings, where gabapentin reduces opioid consumption and improves recovery outcomes. In China, provincial-level procurement tenders and the country's role as a dominant global API producer create a structurally unique market dynamic combining high-volume domestic demand with cost-efficient local supply.

Competitive and Strategic Outlook

The competitive environment is defined by volume-driven generic rivalry, where operational efficiency, cost leadership in API sourcing, and supply chain robustness determine market position. Teva Pharmaceuticals leads as a dominant volume supplier, leveraging large-scale manufacturing capacity and pharmacy benefit manager (PBM) contracting strength across multiple dosage forms. Lupin, drawing on vertically integrated API and finished dosage manufacturing in India, competes through regulatory compliance and competitive pricing in heavily regulated markets including the United States. Pfizer retains a legacy presence through its branded portfolio, concentrating on neurologist relationships and specific approved indications, though its revenue contribution from gabapentin is substantially outpaced by generic volume leaders. Notable recent developments include Sunshine Biopharma's June 2025 launch of generic gabapentin capsules across three strengths in Canada, and the 2023 introduction of Gabapentin ER 300/600 mg in South Korea through a collaboration between Lotus Pharmaceutical and Adalvo, reflecting continued international generic expansion into underserved markets.

Conclusion

The gabapentin market is set for steady, volume-driven growth through 2031, underpinned by the rising global burden of neuropathic pain, the structural shift away from opioid-based analgesia, and the sustained accessibility of generic formulations across diverse healthcare systems. Participants that combine cost-efficient API procurement, regulatory compliance strength, and targeted investment in differentiated ER formulations will be best positioned to sustain competitive advantage in an otherwise commoditized market.

Key Benefits of this Report

  • Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2025 and forecast data from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GABAPENTIN MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Generic
  • 5.3. Branded

6. GABAPENTIN MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Epilepsy
  • 6.3. Neuropathic Pain
  • 6.4. Restless Legs Syndrome
  • 6.5. Others

7. GABAPENTIN MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Others

8. GABAPENTIN MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Pfizer
  • 10.2. Fierce Pharma
  • 10.3. Mayo Clinic
  • 10.4. Ralington Pharma
  • 10.5. Teva Pharmaceuticals
  • 10.6. Gralise
  • 10.7. Glenmark Pharmaceuticals
  • 10.8. Stensa Lifesciences
  • 10.9. Rosemont Pharmaceuticals
  • 10.10. Lupin